Full text is available at the source.
Abstract
Significant within-group changes from baseline to the primary time point were observed for several patient-reported outcome measures in the AWARD clinical trial programme for dulaglutide.
- Dulaglutide 1.5 mg showed significantly greater improvements in the Impact of Weight on Self-Perception score compared to insulin glargine.
- Both doses of dulaglutide led to significantly greater improvements in the Impact of Weight on Ability to Perform Physical Activities of Daily Living score.
- All subscales of the Diabetes Treatment Satisfaction Questionnaire showed significantly greater improvement with both dulaglutide doses compared to exenatide.
- Dulaglutide 1.5 mg resulted in significantly greater improvement on the Diabetes Treatment Satisfaction Questionnaire hyperglycaemia subscale compared to metformin.
- These findings suggest that dulaglutide may be beneficial in the treatment of type 2 diabetes.
Simplified